Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - SELLAS Life Sciences Group, Inc. | sls20191231ex321.htm |
| EX-31.2 - EXHIBIT 31.2 - SELLAS Life Sciences Group, Inc. | sls20191231ex312.htm |
| EX-31.1 - EXHIBIT 31.1 - SELLAS Life Sciences Group, Inc. | sls20191231ex311.htm |
| EX-10.49 - EXHIBIT 10.49 - SELLAS Life Sciences Group, Inc. | sls20191231ex1049.htm |
| EX-10.48 - EXHIBIT 10.48 - SELLAS Life Sciences Group, Inc. | sls20191231ex1048.htm |
| EX-4.41 - EXHIBIT 4.41 - SELLAS Life Sciences Group, Inc. | sls20191231ex441.htm |
| 10-K - 10-K - SELLAS Life Sciences Group, Inc. | sls-20191231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-1 (Nos. 333-225140 and 333-231723), Form S-3 (Nos. 333-213908, 333-224845, 333-226251, and 333-233869) and Form S-8 (Nos. 333-174819, 333-182578, 333-210833, 333-213248, and 333-230741) of SELLAS Life Sciences Group, Inc. (the “Company”), of our report dated March 13, 2020, relating to the consolidated financial statements of the Company, which report expresses an unqualified opinion and includes an explanatory paragraph relating to a going concern emphasis, appearing in this Annual Report on Form 10-K for the year ended December 31, 2019.
/s/ Moss Adams LLP
San Francisco, California
March 13, 2020